华兰疫苗(301207) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 reached ¥1,568,664,139.97, representing a 214.16% increase compared to the same period last year[12]. - Net profit attributable to shareholders for Q3 2023 was ¥521,495,097.44, up 152.51% year-on-year[12]. - Basic earnings per share for Q3 2023 were ¥0.8691, a 151.04% increase year-on-year[12]. - The net profit after deducting non-recurring gains and losses for the first nine months of 2023 was ¥554,821,485.00, reflecting a 22.20% increase compared to the same period last year[12]. - The net profit for the current period is 629,714,837.48, an increase from 504,708,026.11 in the previous period, representing a growth of approximately 24.8%[42]. - Operating profit for the current period is 737,508,632.46, compared to 576,363,372.30 in the previous period, indicating a rise of about 28%[42]. - The total equity attributable to the parent company's shareholders is 6,027,893,516.47, up from 5,496,576,329.45 in the previous period, reflecting an increase of approximately 9.7%[46]. Assets and Liabilities - Total assets as of the end of Q3 2023 amounted to ¥7,807,869,406.53, a 10.35% increase from the end of the previous year[12]. - The total assets at the end of the reporting period amounted to approximately 7.81 billion RMB, an increase from 7.08 billion RMB in the previous period[22]. - The total liabilities increased to approximately 1.78 billion RMB from 1.58 billion RMB in the previous period[22]. - Total current assets increased to ¥5,041,192,871.31 from ¥4,192,738,083.14, showing a growth of 20.29%[39]. - The total liabilities and equity amount to 7,807,869,406.53, compared to 7,075,517,368.83 in the previous period, reflecting an increase of about 10.3%[46]. Cash Flow - The net cash flow from operating activities for the first nine months of 2023 was ¥554,821,485.00, a remarkable increase of 1,477.12% compared to the previous year[14]. - Cash flow from operating activities for the current period is 488,668,014.32, a significant improvement from -35,484,779.81 in the previous period[44]. - The company received cash from sales of goods and services totaling 1,463,305,655.72, compared to 938,656,928.09 in the previous period, representing a growth of about 56%[44]. - Cash and cash equivalents decreased to ¥375,780,768.04 from ¥600,041,864.54, a decline of 37.38%[39]. - Cash and cash equivalents at the end of the period amount to 375,780,768.04, down from 896,022,620.53 at the end of the previous period, indicating a decrease of approximately 58%[49]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 13,591[16]. - The largest shareholder, Hualan Biological Engineering Co., Ltd., holds 67.50% of the shares, totaling 405,000,000 shares[16]. - The number of shares held by the top ten unrestricted shareholders is 32,400,000 and 30,000,700 respectively[16]. - The company has 405 million restricted shares, with 135 million shares newly restricted during the period[18]. - The company plans to lift restrictions on certain shares on August 18, 2025[18]. Research and Development - Research and development expenses for the first nine months of 2023 were ¥71,494,795.96, down 35.06% from the same period in 2022[14]. - The company reported a development expenditure of approximately 25.77 million RMB for the current period[22]. - The company has not indicated any new product launches or technological advancements in the current report[24]. Other Financial Metrics - The fair value change income for the first nine months of 2023 was ¥30,136,820.35, a significant increase of 153.11% year-on-year[14]. - The company reported a significant increase in tax expenses, totaling ¥105,212,998.05 for the first nine months of 2023, which is 48.82% higher than the same period last year[14]. - Total operating revenue for the current period reached ¥1,718,267,831.09, an increase of 10.16% compared to ¥1,559,870,340.76 in the previous period[24]. - Total operating costs amounted to ¥1,047,980,586.15, up from ¥1,007,106,441.39, reflecting a growth of 4.88%[24]. - Investment income increased to ¥52,178,400.41 from ¥40,508,829.67, representing a rise of 28.83%[24]. - Other income rose slightly to ¥8,328,457.98 from ¥8,078,836.06, marking an increase of 3.09%[24]. - The company has a deferred income tax asset of approximately 209.38 million RMB[22]. - Inventory levels rose significantly to ¥291,551,265.80 from ¥167,157,010.74, an increase of 74.38%[39]. - Fixed assets decreased to ¥1,204,003,175.41 from ¥1,283,020,368.71, a decline of 6.15%[39].